Genedata Expands AI Discovery Workflows with NVIDIA BioNeMo Open Models, Including the New RFD4-Proteina Release

Bringing next-generation binder design models into production discovery

BASEL, Switzerland, Oct. 22, 2026 /PRNewswire/ -- Genedata, a Danaher company, and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the addition of the new RFD4-Proteina binder design model into Genedata's AI-enabled discovery workflows, following the model's introduction at NVIDIA GTC Berlin. As an early ecosystem partner, Genedata is among the first companies to make RFD4-Proteina available within its production discovery workflows. By connecting AI-generated molecular designs, scientific data, and laboratory results, Genedata helps researchers transform AI predictions into continuous learning cycles that accelerate biologics discovery.

The workflow begins with scientists defining target characteristics and required properties using Genedata's AI co-scientist. NVIDIA's open protein design models then generate and evaluate candidate binders within Genedata. As candidates move into laboratory testing, results are captured and linked back to the original designs, helping scientists refine and rank the next round.

"Advances in AI are creating unprecedented opportunities for protein and antibody discovery, but unlocking their full value requires more than access to powerful models alone," said Othmar Pfannes, Ph.D., President of Genedata. "Researchers need a way to connect molecular design, experimental execution, and scientific data into a continuous learning process. Genedata serves as the digital backbone that brings these elements together, helping scientists evaluate more candidates before testing, preserve the scientific context behind each outcome, and build knowledge from one discovery cycle to the next."

While advances in generative AI are rapidly expanding what scientists can design, many organizations still struggle to operationalize these models within production scientific research workflows. Genedata provides the orchestration, governance, and scientific data foundation needed to deploy NVIDIA BioNeMo open models, including RFD4-Proteina, directly within the discovery workflows scientists use every day. Researchers can apply AI-generated designs within established processes while maintaining lineage, traceability, and scientific context across the discovery lifecycle.

Within Danaher's autonomous laboratory initiative, these capabilities connect AI, automation, and scientific data in a closed-loop discovery framework where each experimental outcome informs the next design cycle, creating a continuous learn-and-improve process that advances science while keeping scientists in control.

About Genedata
Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharma R&D, transforms biopharma data into intelligence. Our innovative solutions combine deep science, technology, and AI domain knowledge. Leading biopharma organizations and cutting-edge biotechs partner with Genedata to digitalize and automate complex data workflows. Our advanced analytics and embedded AI enable data-driven decisions. From early discovery through development to the clinic, Genedata solutions drive innovation and maximize ROI being trusted by customers worldwide for more than 25 years.

www.genedata.com
LinkedIn | YouTube

About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

View original content to download multimedia:https://www.prnewswire.com/news-releases/genedata-expands-ai-discovery-workflows-with-nvidia-bionemo-open-models-including-the-new-rfd4-proteina-release-302915726.html

SOURCE Genedata